Discovery, Optimization, and Evaluation of Non-Nucleoside SARS-CoV-2 NSP14 Inhibitors.
Miller, M.W., Meyer, C., Garzia, A., Hoffmann, H.H., Khan, T.A., Egbertson, M., Myers, R.W., Liverton, N., Kargman, S., Davis, J.A., Ganichkin, O., Nitsche, J., Steinbacher, S., Dagan, S., Glickman, J.F., Rice, C.M., Tuschl, T., Meinke, P.T., Huggins, D.J.(2025) J Med Chem 
- PubMed: 40910582 
- DOI: https://doi.org/10.1021/acs.jmedchem.5c01155
- Primary Citation of Related Structures:  
9S2V - PubMed Abstract: 
We recently reported the discovery of TDI-015051, a first-in-class small-molecule inhibitor of the SARS-CoV-2 guanine-N7 methyltransferase nonstructural protein 14 (NSP14). NSP14 plays a critical role in viral RNA cap synthesis and its inhibition represents a novel antiviral approach. Utilizing systematic structure-activity relationship studies, potent non-nucleoside-based inhibitors with single-digit nanomolar cellular activity were identified from an HTS hit lacking cellular activity. Thermal shift assay data and available crystal structures led us to develop a model of the novel inhibitory ternary complex (NSP14, SAH, inhibitor), which was validated with a crystal structure of the complex. The advances described here enabled a successful proof-of-concept study that validated SARS-CoV-2 NSP14 as a novel drug target for COVID-19 and represent the first demonstration of pharmacological inhibition of viral methyltransferases as a viable avenue for an antiviral therapeutic.
- Sanders Tri-Institutional Therapeutics Discovery Institute, The Rockefeller University, 1230 York Avenue, New York, New York 10065, United States.
Organizational Affiliation: